Darzalex (daratumumab)

Free

Darzalex (daratumumab) is a targeted monoclonal antibody used to treat multiple myeloma, a cancer that affects plasma cells in the bone marrow, in adults. Darzalex is given as an intravenous (IV) infusion over several hours, and Darzalex Faspro is given as an injection under the skin (subcutaneous injection) over 3 to 5 minutes. darzalex injection price

Description

Darzalex injection price

Darzalex (daratumumab) is a targeted monoclonal antibody used to treat multiple myeloma, a cancer that affects plasma cells in the bone marrow, in adults. Darzalex is given as an intravenous (IV) infusion over several hours, and Darzalex Faspro is given as an injection under the skin (subcutaneous injection) over 3 to 5 minutes. darzalex injection price

Darzalex works by binding to a protein called CD38, which is found at high levels on the surface of multiple myeloma cells, and by triggering the body’s immune system to destroy them. Darzalex is a CD38-directed cytolytic antibody.

Darzalex is not chemotherapy; it is a targeted therapy.

What is Darzalex used for?

Darzalex is FDA-approved to treat multiple myeloma in certain adults. It is approved for use for:

  • Newly diagnosed – transplant eligible: for patients recently diagnosed who are candidates for an autologous stem cell transplant
  • Newly diagnosed – transplant ineligible: for patients recently diagnosed who are not candidates for a stem cell transplant
  • Relapsed or refractory multiple myeloma: for patients whose myeloma has come back after specific treatment (relapsed) or has stopped responding to treatment (refractory)
  • Previously treated multiple myeloma: for patients who have received at least one prior therapy. darzalex injection price

Darzalex Side Effects

Common Side Effects (occurring in 20% or more of patients)

The most frequently reported side effects from FDA clinical trials include:

  • Upper respiratory infection (e.g., stuffy nose, sore throat, sneezing, cough)
  • Neutropenia (low white blood cell count, which may increase risk of infection)
  • Infusion-related reactions (see below)
  • Thrombocytopenia (low platelet count may increase risk of bleeding)
  • Anemia (low red blood cell count, which may cause fatigue or pale skin)
  • Diarrhea or constipation
  • Peripheral sensory neuropathy (tingling, numbness, or nerve pain)
  • Fatigue or weakness (asthenia)
  • Peripheral edema (swelling in hands, ankles, or feet)
  • Nausea
  • Cough
  • Fever
  • Dyspnea (shortness of breath)

Reviews

There are no reviews yet.

Be the first to review “Darzalex (daratumumab)”

Your email address will not be published. Required fields are marked *